Antineoplastic Agents: Hormones and Antagonists
OFUPR1 “Fuprostate tablet” 250 mg/tab
適應症：前列腺癌的輔助治療。
Usual dose:
Hirsutism: 250 mg PO qd.
Metastatic carcinoma of the prostate (stage B2-C): 250 mg PO q8h in conjunction with a luteinizing hormone-releasing hormone (LHRH) agonist; begin 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
Metastatic carcinoma of the prostate (stage D2): 250 mg PO q8h in conjunction with a LHRH agonist; continue until progression.
Adverse effect:
Common: diarrhea, nausea,hot flashes, skin rashes.
Serious: anemia, leukopenia, thrombocytopenia, hepatotoxicity.
Contraindication: hypersensitivity to flutamide or any component of the preparation; Severe hepatic impairmen.
Precautions:
Do not administer to patients with baseline ALT values greater than twice the ULN; baseline monitoring recommended prior to initiating therapy; Not recommended for use in women.
健保給付規定：（90/8/1、101/7/1）
1.晚期（包括T3、淋巴腺轉移、器官轉移）之腫瘤。
2.攝護腺癌病人接受根除性攝護腺切除手術治療後，PSA逐漸升高有局部復發或遠處轉移之情況。
3.癌症臨床期別為T2、T3，準備接受根除性攝護腺切除手術治療或其他定效治療，包括irradiation之前為求tumor volume reduction，作為neoadjuvant治療之目的。